Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction

References

• Wodak A, Crofts N. HIV revisited: preventing the spread of blood-borne viruses among injecting drug users. Aust J Public Health 1994; 18: 239–241
   PubMedGoogle Scholar
• Dore G J, Law M, MacDonald M, Kaldor J M. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003; 26: 171–184
   PubMed Web of Science ®Google Scholar
• Kaldor J M, Dore G J, Correll P K. Public health challenges in hepatitis C virus infection. J Gastroenterol Hepatol 2000; 15(Suppl)E83–E90
   Google Scholar
• Byrne A J, Wodak A. Census of patients receiving methadone treatment in a general practice. Addict Res 1996; 3: 341–349
   Web of Science ®Google Scholar
• Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997; 92: 999–1005
   PubMed Web of Science ®Google Scholar
• Crofts N, Hopper J L, Bowden D S, Breschkin A M, Milner R, Locarnini S A. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993; 159: 237–241
   PubMed Web of Science ®Google Scholar
• Crofts N, Aitken C K. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990 – 1995. Med J Aust 1997; 167: 17–20
   PubMed Web of Science ®Google Scholar
• Hallinan R, Byrne A, Amin J, Dore G J. Hepatitis C virus incidence among injecting drug users on opioid replacement therapy. Aust NZ J Public Health 2004; 28: 576–578
   Google Scholar
• Hallinan R, Byrne A, Amin J, Dore G J. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol 2005; 20: 1082–1086
   PubMed Web of Science ®Google Scholar
• Kapadia F, Latka M H, Hagan H, et al. Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE). J Urban Health 2007; 84: 99–115
   PubMed Web of Science ®Google Scholar
• Strain E C, Bigelow G E, Liebson I A, Stitzer M L. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281: 1000–1005
   PubMed Web of Science ®Google Scholar
• Hallinan R, Ray J, Byrne A, Agho K, Attia J. Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis. Drug Alcohol Depend 2006; 81: 129–136
   PubMed Web of Science ®Google Scholar
• Salsitz E A, Joseph H, Frank B, et al. Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice—a summary report (1983 – 1998). Mt Sinai J Med 2000; 67: 388–397
   PubMed Web of Science ®Google Scholar
• Schmitz J M, Rhoades H M, Elk R, Creson D, Hussein I, Grabowski J. Medication take-home doses and contingency management. Exp Clin Psychopharmacol 1998; 6: 162–168
   PubMed Web of Science ®Google Scholar
• Rhoades H M, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998; 88: 34–39
   PubMed Web of Science ®Google Scholar
• Hartel D M, Schoenbaum E E. Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep 1998; 113(Suppl 1)107–115
   PubMedGoogle Scholar
• Brady T M, Salvucci S, Sverdlov L S, et al. Methadone dosage and retention: an examination of the 60 mg/day threshold. J Addict Dis 2005; 24: 23–47
   PubMed Web of Science ®Google Scholar
• D'Aunno T, Pollack H A. Changes in methadone treatment practices: results from a national panel study, 1988 – 2000. JAMA 2002; 288: 850–856
   PubMed Web of Science ®Google Scholar
• Stoove M A, Gifford S M, Dore G J. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 2005; 77: 81–86
   PubMed Web of Science ®Google Scholar
• Dore G J, Thomas D L. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005; 25: 18–32
   PubMed Web of Science ®Google Scholar
• Jauffret-Roustide M, Emmanuelli J, Desenclos J C. [Limited impact of the harm-reduction policy on HCV among drug-users. The ANRS – Coquelicot survey example]. Rev Epidemiol Sante Publique 2006; 54(Spec 1)1S53–1S59
   Google Scholar
• Weaver M F, Cropsey K L, Fox S A. HCV prevalence in methadone maintenance: self-report versus serum test. Am J Health Behav 2005; 29: 387–394
   Google Scholar
• Mark K E, Murray P J, Callahan D B, Gunn R A. Medical care and alcohol use after testing hepatitis C antibody positive at STD clinic and HIV test site screening programs. Public Health Rep 2007; 122: 37–43
   PubMed Web of Science ®Google Scholar
• Campbell J V, Hagan H, Latka M H, et al. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend 2006; 81: 259–265
   PubMed Web of Science ®Google Scholar
• Dore G. Therapy decision-making for people with chronic hepatitis C. Hepatitis C: an Australian perspective, N Crofts, G Dore, S Locarnini. IP Communications, Melbourne 2001; 178–179
   Google Scholar
• Hallinan R, Byrne A, Agho K, Dore G J. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007; 88: 49–53
   PubMed Web of Science ®Google Scholar
• Dalgard 3O, Bjoro K, Hellum K. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8: 45–49
   PubMed Web of Science ®Google Scholar
• Backmund M, Meyer K, Edlin B R. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39: 1540–1543
   Google Scholar
• Hagan H, Strauss S M, Astone J M, Des Jarlais D C. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clin Infect Dis 2005; 40(Suppl 5)S297–S303
   Google Scholar
• Verrando R, Robaeys G, Mathei C, Buntinx F. Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. Acta Gastroenterol Belg 2005; 68: 81–85
   PubMed Web of Science ®Google Scholar
• Strauss S M, Astone J M, Des Jarlais D C, Hagan H. Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units. AIDS Patient Care STDS 2005; 19: 78–88
   Google Scholar
• Clanon K A, Johannes Mueller J, Harank M. Integrating treatment for hepatitis C virus infection into an HIV clinic. Clin Infect Dis 2005; 40(Suppl 5)S362–S366
   Google Scholar
• Gunn R A, Lee M A, Callahan D B, Gonzales P, Murray P J, Margolis H S. Integrating hepatitis, STD, and HIV services into a drug rehabilitation program. Am J Prev Med 2005; 29: 27–33
   PubMed Web of Science ®Google Scholar
• Edlin B R, Kresina T F, Raymond D B. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40(Suppl 5)S276–S285
   PubMed Web of Science ®Google Scholar
• Budd J, Robertson R. Hepatitis C and general practice: the crucial role of primary care in stemming the epidemic. Br J Gen Pract 2005; 55: 259–260
   PubMedGoogle Scholar
• Kresina T F, Khalsa J, Cesari H, Francis H. Hepatitis C virus infection and substance abuse: medical management and developing models of integrated care—an introduction. Clin Infect Dis 2005; 40(Suppl 5)S259–S262
   Google Scholar
• Flanigan T P, Taylor L E, Mitty J A. Use of community-based, directly observed therapy for HIV infection: lessons learned for treatment of hepatitis C virus infection. Clin Infect Dis 2005; 40(Suppl 5)S346–S348
   Google Scholar
• Litwin A H, Soloway I, Gourevitch M N. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 2005; 40(Suppl 5)S33–S45
   Google Scholar
• Friedmann P D, D'Aunno T A, Jin L, Alexander J A. Medical and psychosocial services in drug abuse treatment: do stronger linkages promote client utilization?. Health Serv Res 2000; 35: 443–465
   PubMed Web of Science ®Google Scholar